1. Home
  2. BGLC vs MBIO Comparison

BGLC vs MBIO Comparison

Compare BGLC & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BioNexus Gene Lab Corp

BGLC

BioNexus Gene Lab Corp

N/A

Current Price

$1.39

Market Cap

3.8M

Sector

Health Care

ML Signal

N/A

MBIO

Mustang Bio Inc.

HOLD

Current Price

$0.40

Market Cap

4.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGLC
MBIO
Founded
2017
2015
Country
Malaysia
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8M
4.1M
IPO Year
2019
2023

Fundamental Metrics

Financial Performance
Metric
BGLC
MBIO
Price
$1.39
$0.40
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
7.4K
★ 33.0K
Earning Date
11-13-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
45.78
★ 98.99
EPS
N/A
★ N/A
Revenue
★ $7,424,911.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$405.45
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.07
$0.38
52 Week High
$5.85
$1.69

Technical Indicators

Market Signals
Indicator
BGLC
MBIO
Relative Strength Index (RSI) 49.98 23.47
Support Level $1.34 N/A
Resistance Level $1.61 $0.56
Average True Range (ATR) 0.10 0.03
MACD 0.01 -0.01
Stochastic Oscillator 64.71 11.48

Price Performance

Historical Comparison
BGLC
MBIO

About BGLC BioNexus Gene Lab Corp

BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Share on Social Networks: